Total Payments
$25,962
2024 Payments
$6,531
Companies
12
Transactions
31
Medicare Patients
963
Medicare Billing
$139,116
Payment Breakdown by Category
Consulting$16,437 (63.3%)
Other$7,230 (27.8%)
Food & Beverage$1,203 (4.6%)
Travel$1,083 (4.2%)
Education$9.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,437 | 10 | 63.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,230 | 2 | 16.3% |
| Honoraria | $3,000 | 1 | 11.6% |
| Food and Beverage | $1,203 | 13 | 4.6% |
| Travel and Lodging | $1,083 | 4 | 4.2% |
| Education | $9.42 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $6,170 | 10 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $5,054 | 9 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $4,074 | 3 | $0 (2022) |
| Advanced Accelerator Applications | $2,500 | 1 | $0 (2020) |
| LANTHEUS MEDICAL IMAGING, INC. | $2,430 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,135 | 1 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $1,750 | 1 | $0 (2020) |
| PFIZER INC. | $1,500 | 1 | $0 (2020) |
| Celularity Inc. | $175.56 | 1 | $0 (2022) |
| AstraZeneca AB | $134.99 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,531 | 7 | Exelixis Inc. ($4,101) |
| 2023 | $2,161 | 2 | Merck Sharp & Dohme LLC ($2,135) |
| 2022 | $400.09 | 2 | Novartis Pharmaceuticals Corporation ($224.53) |
| 2020 | $5,885 | 4 | Advanced Accelerator Applications ($2,500) |
| 2019 | $1,427 | 4 | Lexicon Pharmaceuticals, Inc. ($1,427) |
| 2018 | $7,478 | 7 | Novartis Pharmaceuticals Corporation ($3,849) |
| 2017 | $2,081 | 5 | Exelixis Inc. ($2,069) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| 03/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $508.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $299.79 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $97.58 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $55.15 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/26/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 05/09/2023 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Endo-Mechanical | ||||||
| 09/17/2022 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $224.53 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2022 | Celularity Inc. | — | Food and Beverage | In-kind items and services | $175.56 | General |
| 08/12/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 06/10/2020 | Advanced Accelerator Applications | LUTATHERA (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2020 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 01/23/2020 | AstraZeneca AB | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $134.99 | General |
| Category: Oncology | ||||||
| 11/01/2019 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| 07/23/2019 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 05/03/2019 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 05/03/2019 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $301.50 | General |
| 12/18/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Oncology | ||||||
| 10/03/2018 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 10/03/2018 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $128.75 | General |
| 10/02/2018 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $102.65 | General |
| 06/01/2018 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2018 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $99.07 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 239 | 362 | $68,650 | $29,681 |
| 2022 | 4 | 233 | 438 | $68,819 | $36,613 |
| 2021 | 7 | 250 | 452 | $83,712 | $44,836 |
| 2020 | 7 | 241 | 385 | $69,492 | $27,986 |
Total Patients
963
Total Services
1,637
Medicare Billing
$139,116
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 88 | $14,661 | $6,707 | 45.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 89 | $15,019 | $6,703 | 44.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 61 | $16,416 | $6,637 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 39 | $10,428 | $4,632 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 41 | $3,813 | $2,136 | 56.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 33 | $3,484 | $1,497 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,829 | $1,369 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 58 | 101 | $14,140 | $7,943 | 56.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 96 | $13,575 | $7,684 | 56.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 82 | $15,252 | $6,972 | 45.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 56 | $12,455 | $6,538 | 52.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 29 | $6,380 | $3,550 | 55.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 32 | 40 | $3,720 | $2,072 | 55.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 25 | 34 | $3,297 | $1,853 | 56.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 43 | 78 | $17,545 | $9,708 | 55.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 96 | $17,551 | $8,377 | 47.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 47 | 80 | $11,200 | $6,515 | 58.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 35 | 52 | $11,570 | $6,507 | 56.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 75 | $10,625 | $6,258 | 58.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $5,525 | $2,877 | 52.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $5,325 | $2,371 | 44.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 27 | $2,511 | $1,488 | 59.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 12 | $1,860 | $734.28 | 39.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 141 | $19,740 | $8,803 | 44.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $10,065 | $4,130 | 41.0% |
About Dr. Jennifer Eads, M.D
Dr. Jennifer Eads, M.D is a Medical Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1487842100.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Eads, M.D has received a total of $25,962 in payments from pharmaceutical and medical device companies, with $6,531 received in 2024. These payments were reported across 31 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($16,437).
As a Medicare-enrolled provider, Eads has provided services to 963 Medicare beneficiaries, totaling 1,637 services with total Medicare billing of $139,116. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Philadelphia, PA
- Active Since 10/09/2007
- Last Updated 09/12/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487842100
Products in Payments
- CABOMETYX (Drug) $4,101
- SANDOSTATIN LAR (Drug) $3,849
- LUTATHERA (Drug) $2,725
- Cabometyx (Drug) $2,069
- SOMATULINE DEPOT (Drug) $1,750
- IMFINZI (Drug) $134.99
- Monarch Platform (Device) $25.77
- Xermelo (Drug) $20.80
- Abraxane (Drug) $13.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Philadelphia
Daniel Haller, Md, MD
Medical Oncology — Payments: $744,976
Medical Oncology $744,976
Adam Cohen, Md, MD
Medical Oncology — Payments: $302,018
Medical Oncology $302,018
Dr. Jean-Pierre Issa, M.d, M.D
Medical Oncology — Payments: $223,097
Medical Oncology $223,097
Alexander Perl, Md, MD
Medical Oncology — Payments: $218,549
Medical Oncology $218,549
Carl June, Md, MD
Medical Oncology — Payments: $140,824
Medical Oncology $140,824
Anthony Olszanski, M.d, M.D
Medical Oncology — Payments: $131,641
Medical Oncology $131,641